CZ291039B6 - Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek - Google Patents

Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek Download PDF

Info

Publication number
CZ291039B6
CZ291039B6 CZ19941910A CZ191094A CZ291039B6 CZ 291039 B6 CZ291039 B6 CZ 291039B6 CZ 19941910 A CZ19941910 A CZ 19941910A CZ 191094 A CZ191094 A CZ 191094A CZ 291039 B6 CZ291039 B6 CZ 291039B6
Authority
CZ
Czechia
Prior art keywords
sequence
amino acid
monoclonal antibody
variable region
seq
Prior art date
Application number
CZ19941910A
Other languages
Czech (cs)
English (en)
Other versions
CZ191094A3 (en
Inventor
Chuan-Chu Chou
Nicholas J. Murgolo
John S. Abrams
Chung-Her Jehn
Mary E. Petro
Jon E. Silver
Stephen Tindall
William T. Windsor
Paul J. Zavodny
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CZ191094A3 publication Critical patent/CZ191094A3/cs
Publication of CZ291039B6 publication Critical patent/CZ291039B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CZ19941910A 1992-02-06 1993-02-04 Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek CZ291039B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06

Publications (2)

Publication Number Publication Date
CZ191094A3 CZ191094A3 (en) 1994-12-15
CZ291039B6 true CZ291039B6 (cs) 2002-12-11

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ19941910A CZ291039B6 (cs) 1992-02-06 1993-02-04 Monoklonální protilátka, hybridom, polypeptid a způsob jeho přípravy, izolovaná DNA, rekombinantní vektor, hostitelská buňka, humanizovaná protilátka a farmaceutický prostředek

Country Status (21)

Country Link
US (1) US6451982B1 (OSRAM)
EP (1) EP0625201A1 (OSRAM)
JP (2) JPH07505767A (OSRAM)
KR (2) KR0150060B1 (OSRAM)
CN (1) CN1077991A (OSRAM)
AR (1) AR248044A1 (OSRAM)
AU (1) AU683836B2 (OSRAM)
CA (1) CA2129445A1 (OSRAM)
CZ (1) CZ291039B6 (OSRAM)
FI (1) FI943635L (OSRAM)
HU (1) HUT67943A (OSRAM)
IL (1) IL104620A (OSRAM)
NO (1) NO942912L (OSRAM)
NZ (1) NZ249633A (OSRAM)
PL (1) PL176393B1 (OSRAM)
RU (1) RU94045919A (OSRAM)
SG (1) SG49597A1 (OSRAM)
SK (1) SK280610B6 (OSRAM)
TN (1) TNSN93012A1 (OSRAM)
WO (1) WO1993016184A1 (OSRAM)
ZA (1) ZA93779B (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
ATE346867T1 (de) * 1994-12-23 2006-12-15 Smithkline Beecham Corp Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
CA2957200C (en) * 2002-10-16 2020-05-26 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
JP4954709B2 (ja) 2004-10-28 2012-06-20 協和発酵キリン株式会社 子宮内膜症治療剤
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
JP2010526087A (ja) 2007-04-30 2010-07-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗ｉｌ−５抗体を投与するための方法
JP5917143B2 (ja) 2008-03-28 2016-05-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 処置方法
WO2010046094A1 (en) * 2008-10-23 2010-04-29 F. Hoffmann-La Roche Ag Determination of immunoglobulin encoding nucleid acid
CA2824279A1 (en) * 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
DK3191513T3 (da) 2014-09-08 2020-08-24 Cephalon Inc Anvendelse af reslizumab til behandling af moderat til svær eosinofil astma
CN116327922A (zh) 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
WO2018226339A1 (en) 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
JP7307720B2 (ja) * 2017-09-29 2023-07-12 江蘇恒瑞医薬股▲ふん▼有限公司 Ｉｌ－５抗体、その抗原結合フラグメント、およびそれらの医薬適用
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
ES2062032T3 (es) * 1988-11-03 1994-12-16 Schering Corp Antagonista de interleuquina-5 para prevenir o reducir la eosinofilia.
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
SG49597A1 (en) 1992-02-06 1998-06-15 Schering Corp Design cloning and expression of humanized monoclonal antibodies against human interleukin-5

Also Published As

Publication number Publication date
AR248044A1 (es) 1995-05-31
IL104620A0 (en) 1993-06-10
CA2129445A1 (en) 1993-08-07
ZA93779B (en) 1993-08-05
EP0625201A1 (en) 1994-11-23
KR950700413A (ko) 1995-01-16
JPH07505767A (ja) 1995-06-29
FI943635A0 (fi) 1994-08-05
SK280610B6 (sk) 2000-05-16
NO942912D0 (OSRAM) 1994-08-05
WO1993016184A1 (en) 1993-08-19
FI943635A7 (fi) 1994-08-05
NO942912L (no) 1994-10-06
RU94045919A (ru) 1996-11-10
CN1077991A (zh) 1993-11-03
US6451982B1 (en) 2002-09-17
AU3656093A (en) 1993-09-03
SG49597A1 (en) 1998-06-15
TNSN93012A1 (fr) 1994-03-17
CZ191094A3 (en) 1994-12-15
HUT67943A (en) 1995-05-29
SK91894A3 (en) 1995-02-08
NZ249633A (en) 1995-12-21
IL104620A (en) 2000-02-29
JP2000210097A (ja) 2000-08-02
AU683836B2 (en) 1997-11-27
KR0150060B1 (ko) 1998-08-17
HU9402293D0 (en) 1994-10-28
FI943635L (fi) 1994-08-05
PL176393B1 (pl) 1999-05-31

Similar Documents

Publication Publication Date Title
US6451982B1 (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
US5863537A (en) Humanized monoclonal antibodies against human interleukin-4
JP3946256B2 (ja) ヒトインターロイキン５受容体α鎖に対する抗体
CN101802015B (zh) 双特异性抗体及其制造方法
US6056957A (en) Humanized monoclonal antibodies against human interleukin-5
US8232372B2 (en) Engineered anti-TSLP antibody
KR100697120B1 (ko) Ｉｌ-18 매개 질환의 치료에 유용한 재조합 ｉｌ-18 길항제
US5705154A (en) Humanized monoclonal antibodies against human interleukin-4
CN112334483B (zh) 抗IL-23p19抗体及其用途
RS55788B1 (sr) Inženjerisana anti-il-23 antitela
JP2011511638A (ja) 抗ｔｓｌｐｒ抗体の設計製作
WO1995001997A1 (en) RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
JP2002514421A (ja) Ｃｄ２３に対する抗体、それらの誘導体、及びそれらの治療的使用
JP2001509817A (ja) 抗ｖｅｇｆ抗体
SK33396A3 (en) Fusion protein with specific bond to human interleukin-4 and pharmaceutical composition containing its
EP1708961B1 (en) Anti-ip-10 antibodies
RU2854833C1 (ru) Биспецифические канинизированные антитела и биспецифические партнеры по связыванию для лечения атопического дерматита
KR100509993B1 (ko) Il-5 매개된 질환의 치료에 유용한 재조합 il-5 길항제
AU2013203837A1 (en) Engineered anti-tslp antibody
HK1184172A (en) Engineered anti-tslp antibody

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 19930204